Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.95 Million CAD | -130.08% |
| 2022 | 3.72 Million CAD | -34.1% |
| 2021 | 5.65 Million CAD | 3319.4% |
| 2020 | -2.91 Million CAD | -90.14% |
| 2019 | 1.67 Million CAD | 110.01% |
| 2018 | -7.07 Million CAD | 336.27% |
| 2017 | -2.79 Million CAD | -126.99% |
| 2016 | 1.25 Million CAD | -17.14% |
| 2015 | 1.51 Million CAD | -12.55% |
| 2014 | 1.72 Million CAD | 47.24% |
| 2013 | 1.26 Million CAD | 202.6% |
| 2012 | -1.24 Million CAD | 2.72% |
| 2011 | -1.17 Million CAD | 1.4% |
| 2010 | -1.19 Million CAD | 9.16% |
| 2009 | -1.31 Million CAD | 58.08% |
| 2008 | -3.13 Million CAD | -51.58% |
| 2007 | -2.06 Million CAD | -23.43% |
| 2006 | -1.67 Million CAD | -627.48% |
| 2005 | 317.6 Thousand CAD | 214.03% |
| 2004 | 101.13 Thousand CAD | 137.13% |
| 2003 | -272.41 Thousand CAD | -202.08% |
| 2002 | 266.86 Thousand CAD | -45.92% |
| 2001 | 493.43 Thousand CAD | 364.87% |
| 2000 | -186.29 Thousand CAD | 95.67% |
| 1999 | -4.4 Million CAD | -152.94% |
| 1998 | -1.9 Million CAD | -1800.0% |
| 1997 | 100 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.95 Million CAD | 21.15% |
| 2024 Q2 | 863.21 Thousand CAD | -71.85% |
| 2024 Q3 | 591.97 Thousand CAD | 4.75% |
| 2023 Q3 | -246.81 Thousand CAD | -146.1% |
| 2023 Q2 | 535.41 Thousand CAD | 162.04% |
| 2023 Q1 | -863.01 Thousand CAD | -1030.93% |
| 2023 FY | - CAD | -130.08% |
| 2023 Q4 | 2.53 Million CAD | 1125.67% |
| 2022 Q2 | 1.19 Million CAD | -11.13% |
| 2022 Q1 | 1.34 Million CAD | -25.61% |
| 2022 FY | - CAD | -34.1% |
| 2022 Q4 | 92.7 Thousand CAD | -91.55% |
| 2022 Q3 | 1.09 Million CAD | -8.22% |
| 2021 Q2 | 1.28 Million CAD | 127.29% |
| 2021 FY | - CAD | 3319.4% |
| 2021 Q3 | 1.99 Million CAD | 54.66% |
| 2021 Q4 | 1.8 Million CAD | -9.37% |
| 2021 Q1 | 567.33 Thousand CAD | 119.01% |
| 2020 Q3 | -5195.00 CAD | -102.35% |
| 2020 Q4 | -2.98 Million CAD | -57346.37% |
| 2020 FY | - CAD | -90.14% |
| 2020 Q1 | -148.34 Thousand CAD | -152.56% |
| 2020 Q2 | 220.75 Thousand CAD | 248.82% |
| 2019 Q1 | 278.39 Thousand CAD | 199.07% |
| 2019 Q2 | 895.23 Thousand CAD | 221.57% |
| 2019 FY | - CAD | 110.01% |
| 2019 Q4 | 282.21 Thousand CAD | 26.7% |
| 2019 Q3 | 222.73 Thousand CAD | -75.12% |
| 2018 Q3 | 391.73 Thousand CAD | 949.35% |
| 2018 Q2 | 37.33 Thousand CAD | -86.53% |
| 2018 Q1 | 277.14 Thousand CAD | 157.92% |
| 2018 Q4 | 93.08 Thousand CAD | -76.24% |
| 2018 FY | - CAD | 336.27% |
| 2017 FY | - CAD | -126.99% |
| 2017 Q1 | -463.58 Thousand CAD | -158.43% |
| 2017 Q4 | -478.52 Thousand CAD | -380.26% |
| 2017 Q3 | 170.74 Thousand CAD | -60.57% |
| 2017 Q2 | 433.06 Thousand CAD | 193.42% |
| 2016 Q4 | 793.46 Thousand CAD | 441.85% |
| 2016 FY | - CAD | -17.14% |
| 2016 Q1 | -146.39 Thousand CAD | -139.34% |
| 2016 Q2 | 459.83 Thousand CAD | 414.11% |
| 2016 Q3 | 146.43 Thousand CAD | -68.15% |
| 2015 Q2 | 316.62 Thousand CAD | -20.54% |
| 2015 Q1 | 398.46 Thousand CAD | 452.81% |
| 2015 Q4 | 372.15 Thousand CAD | -12.52% |
| 2015 Q3 | 425.39 Thousand CAD | 34.35% |
| 2015 FY | - CAD | -12.55% |
| 2014 Q3 | 621.19 Thousand CAD | 13.58% |
| 2014 FY | - CAD | 47.24% |
| 2014 Q4 | 72.08 Thousand CAD | -88.4% |
| 2014 Q2 | 546.91 Thousand CAD | 12.22% |
| 2014 Q1 | 487.34 Thousand CAD | -43.88% |
| 2013 Q4 | 868.38 Thousand CAD | 221.89% |
| 2013 Q2 | 385.13 Thousand CAD | 210.51% |
| 2013 Q1 | -348.5 Thousand CAD | -144.76% |
| 2013 Q3 | 269.77 Thousand CAD | -29.95% |
| 2013 FY | - CAD | 202.6% |
| 2012 FY | - CAD | 2.72% |
| 2012 Q3 | 834.79 Thousand CAD | 445.1% |
| 2012 Q2 | -241.9 Thousand CAD | -47.62% |
| 2012 Q1 | -163.87 Thousand CAD | -6.58% |
| 2012 Q4 | -142.38 Thousand CAD | -117.06% |
| 2011 Q4 | -153.75 Thousand CAD | 59.13% |
| 2011 Q2 | -166.1 Thousand CAD | 56.49% |
| 2011 Q1 | -381.79 Thousand CAD | -219.96% |
| 2011 Q3 | -376.17 Thousand CAD | -126.47% |
| 2011 FY | - CAD | 1.4% |
| 2010 Q2 | -224.46 Thousand CAD | 42.55% |
| 2010 Q4 | 318.27 Thousand CAD | 135.49% |
| 2010 FY | - CAD | 9.16% |
| 2010 Q1 | -390.7 Thousand CAD | -185.14% |
| 2010 Q3 | -896.78 Thousand CAD | -299.52% |
| 2009 Q3 | -350.31 Thousand CAD | 35.69% |
| 2009 Q2 | -544.72 Thousand CAD | -75.19% |
| 2009 Q1 | -310.93 Thousand CAD | 35.93% |
| 2009 FY | - CAD | 58.08% |
| 2009 Q4 | -137.02 Thousand CAD | 60.89% |
| 2008 Q3 | -709.7 Thousand CAD | 37.27% |
| 2008 Q4 | -485.29 Thousand CAD | 31.62% |
| 2008 Q2 | -1.13 Million CAD | -34.59% |
| 2008 Q1 | -840.6 Thousand CAD | -33.86% |
| 2008 FY | - CAD | -51.58% |
| 2007 Q4 | -627.97 Thousand CAD | 17.91% |
| 2007 Q3 | -765.03 Thousand CAD | -139.59% |
| 2007 Q2 | -319.31 Thousand CAD | 9.62% |
| 2007 Q1 | -353.29 Thousand CAD | 69.96% |
| 2007 FY | - CAD | -23.43% |
| 2006 Q4 | -1.17 Million CAD | -778.62% |
| 2006 Q3 | -133.86 Thousand CAD | 54.58% |
| 2006 Q2 | -294.75 Thousand CAD | -324.61% |
| 2006 FY | - CAD | -627.48% |
| 2006 Q1 | -69.41 Thousand CAD | -966.98% |
| 2005 Q2 | 152.58 Thousand CAD | 128.33% |
| 2005 FY | - CAD | 214.03% |
| 2005 Q1 | 66.82 Thousand CAD | -87.4% |
| 2005 Q4 | -6506.00 CAD | -106.21% |
| 2005 Q3 | 104.7 Thousand CAD | -31.38% |
| 2004 FY | - CAD | 137.13% |
| 2004 Q2 | -42.42 Thousand CAD | 68.93% |
| 2004 Q3 | -250.19 Thousand CAD | -489.68% |
| 2004 Q4 | 530.33 Thousand CAD | 311.97% |
| 2004 Q1 | -136.57 Thousand CAD | -126.39% |
| 2003 Q3 | -78.38 Thousand CAD | -82.64% |
| 2003 Q2 | -67.96 Thousand CAD | 75.82% |
| 2003 Q1 | -125.98 Thousand CAD | -166.57% |
| 2003 FY | - CAD | -202.08% |
| 2003 Q4 | -60.32 Thousand CAD | -8.42% |
| 2002 Q2 | 86.07 Thousand CAD | 163.38% |
| 2002 Q4 | 189.24 Thousand CAD | 48.61% |
| 2002 Q3 | 127.34 Thousand CAD | 47.95% |
| 2002 FY | - CAD | -45.92% |
| 2002 Q1 | -135.79 Thousand CAD | -332.53% |
| 2001 Q4 | 58.4 Thousand CAD | -52.41% |
| 2001 Q3 | 122.72 Thousand CAD | -25.14% |
| 2001 Q2 | 163.94 Thousand CAD | 7.68% |
| 2001 Q1 | 152.25 Thousand CAD | 1010.94% |
| 2001 FY | - CAD | 364.87% |
| 2000 FY | - CAD | 95.67% |
| 2000 Q4 | 13.7 Thousand CAD | 0.0% |
| 2000 Q3 | - CAD | 100.0% |
| 2000 Q2 | -200 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 1999 Q2 | -500 Thousand CAD | -66.67% |
| 1999 Q3 | -100 Thousand CAD | 80.0% |
| 1999 Q1 | -300 Thousand CAD | -250.0% |
| 1999 Q4 | -3.3 Million CAD | -3200.0% |
| 1999 FY | - CAD | -152.94% |
| 1998 Q4 | 200 Thousand CAD | 200.0% |
| 1998 Q3 | -200 Thousand CAD | 81.82% |
| 1998 Q2 | -1.1 Million CAD | -83.33% |
| 1998 FY | - CAD | -1800.0% |
| 1998 Q1 | -600 Thousand CAD | -200.0% |
| 1997 Q1 | - CAD | 0.0% |
| 1997 Q4 | -200 Thousand CAD | -200.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | 193.355% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 105.233% |
| Helix BioPharma Corp. | -9.38 Million CAD | 120.844% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | 110.482% |
| Satellos Bioscience Inc. | -15.7 Million CAD | 112.461% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 105.806% |
| Sernova Corp. | -40.19 Million CAD | 104.869% |